Ross Steven Federman

Title: Ross Steven Federman: Innovator in Antigen Binding Molecules

Introduction

Ross Steven Federman is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding molecules. With a total of 2 patents, his work focuses on addressing critical health challenges, including viral infections.

Latest Patents

One of Federman's latest patents is titled "Antigen Binding Molecules Targeting SARS-CoV-2." This invention provides various embodiments of polypeptides that specifically bind to the Spike glycoprotein of severe acute respiratory syndrome coronavirus, particularly SARS-CoV-2-Spike. The invention also includes fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors, and host cells suitable for expressing the polypeptides. Additionally, it outlines methods for treating viral infections, such as COVID-19.

Career Highlights

Federman is currently associated with Flagship Pioneering Innovations Vi, LLC, where he continues to push the boundaries of scientific research and innovation. His work is instrumental in developing solutions that can potentially mitigate the impact of viral diseases.

Collaborations

Some of his notable coworkers include John Ingraham and Cheuk Lun Leung, who contribute to the collaborative efforts in advancing their research initiatives.

Conclusion

Ross Steven Federman's innovative work in the field of antigen binding molecules showcases his commitment to addressing pressing health issues. His contributions are vital in the ongoing fight against viral infections, particularly in the context of the COVID-19 pandemic.